Drug intelligence / Profile preview

TRx-0037

Development stage: Phase 1
Lead developer: TauRx Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

TRx-0037 is a small molecule drug developed as a peptide aggregation inhibitor, specifically targeting the inhibition of tau protein aggregation. It was initially developed by TauRx Pharmaceuticals for the treatment of Alzheimer's disease and other nervous system diseases. The drug acts as an oral tau modulator and was investigated in clinical trials to assess its safety, tolerability, and pharmacokinetics in elderly volunteers. Its development has been discontinued after reaching Phase 1 clinical trials[1][2][3].

Other names: TRx0037TRx-0037TRx 0037

Targets

Tau aggregates (Microtubule-associated protein tau (pathological form))

Beyond the preview

Go deeper on TRx-0037.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRx-0037.

Explore the full profile